# A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

> **NCT06647069** · PHASE1 · RECRUITING · sponsor: **Sanofi** · enrollment: 62 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)
- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** SAR448501

## Key facts

- **NCT ID:** NCT06647069
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-27
- **Primary completion:** 2029-06-25
- **Final completion:** 2029-06-25
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06647069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06647069, "A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06647069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*